Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR-Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA
M Tsuboi, W Weder, C Escriu, C Blakely, J He… - Future …, 2021 - Taylor & Francis
Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …
Prevention of cardiac surgery–associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: The PrevAKI …
A Zarbock, M Küllmar, M Ostermann… - Anesthesia & …, 2021 - journals.lww.com
BACKGROUND: Prospective, single-center trials have shown that the implementation of the
Kidney Disease: Improving Global Outcomes (KDIGO) recommendations in high-risk …
Kidney Disease: Improving Global Outcomes (KDIGO) recommendations in high-risk …
[HTML][HTML] Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized …
M Meersch, C Schmidt, A Hoffmeier, H Van Aken… - Intensive care …, 2017 - Springer
Purpose Care bundles are recommended in patients at high risk for acute kidney injury
(AKI), although they have not been proven to improve outcomes. We sought to establish the …
(AKI), although they have not been proven to improve outcomes. We sought to establish the …
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A …
WZ Zhong, KN Chen, C Chen, CD Gu… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
S Wang, Y Song, D Liu - Cancer Letters, 2017 - Elsevier
The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686
(rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M …
(rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M …
[HTML][HTML] Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
S Wang, S Cang, D Liu - Journal of hematology & oncology, 2016 - Springer
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are
widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M …
widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M …
[HTML][HTML] Second-and third-generation ALK inhibitors for non-small cell lung cancer
J Wu, J Savooji, D Liu - Journal of hematology & oncology, 2016 - Springer
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated
non-small cell lung cancer (NSCLC). Second-and third-generation ALK inhibitors are …
non-small cell lung cancer (NSCLC). Second-and third-generation ALK inhibitors are …
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
L Xiong, R Li, J Sun, Y Lou, W Zhang, H Bai… - The …, 2019 - academic.oup.com
Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …
[HTML][HTML] Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non–small cell lung cancer: A phase II study
Y Zhang, F Fu, H Hu, S Wang, Y Li, H Hu… - The Journal of Thoracic …, 2021 - Elsevier
Introduction Currently, limited data on tyrosine kinase inhibitors as neoadjuvant therapy
exist. This prospective study aimed to investigate the efficacy and safety of preoperative …
exist. This prospective study aimed to investigate the efficacy and safety of preoperative …